January 24, 2025
Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years
Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare
AstraZeneca Invests $570M in Canadian Expansion, Creating 700 New Jobs
AstraZeneca, Canadian expansion, $570M investment, 700 new jobs, life sciences, R&D, clinical trials, pharmaceutical industry
RFK Jr.’s Financial Ties to Gardasil Litigation Spark Conflict-of-Interest Concerns
RFK Jr., Gardasil, Merck, Conflict of Interest, Vaccine Litigation, HHS Secretary Nomination
Vigil Neuroscience’s Oral Alzheimer’s Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi’s Strategic Support
Vigil Neuroscience, VG-3927, Alzheimer’s disease, Phase 1 clinical trial, Sanofi strategic investment, TREM2 agonist program, Microglia therapy
FDA Issues Boxed Warning for Anaphylaxis Risk with Multiple Sclerosis Drugs Copaxone and Glatopa
FDA, boxed warning, anaphylaxis, multiple sclerosis, Copaxone, Glatopa, glatiramer acetate, Teva, Sandoz
FDA Delays Decision on Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Until April 2025
Barth Syndrome, Elamipretide, FDA Decision, Stealth BioTherapeutics, Drug Approval Delay
Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology
Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.